openPR Logo
Press release

Primary Biliary Cholangitis (PBC) Treatment Market| 2017-2027 Key Players Intercept Pharmaceuticals, Inc., Actavis, Inc.

02-12-2019 03:40 PM CET | Health & Medicine

Press release from: future market insights.

Primary Biliary Cholangitis (PBC) Treatment Market| 2017-2027

Primary biliary cholangitis is also referred as primary biliary cirrhosis, is an autoimmune disease of liver that manifest into progressive cholestasis and lead to end-stage liver disease. Primary biliary cholangitis characterized by destruction of bile duct which transport the bile acid. Primary biliary cholangitis is detected in the late stage of disease. Primary biliary cirrhosis majorly seen in women’s in fourth or sixth decades of life. Primary biliary cholangitis generally diagnosed during routine blood examination which presents symptoms like fatigue, pertussis, and right upper quadrant discomfort. In initial examination finding the disease is normal, as the disease advances present symptoms of liver cirrhosis. The hallmark of primary biliary cirrhosis is the presence of antimitochondrial antibodies (AMAs) in the blood. Medical management of primary biliary cirrhosis mainly done to slow the symptom progression and to alleviate the symptoms.

Primary Biliary Cholangitis Treatment Market: Drivers and Restraints

Global primary biliary cholangitis treatment market is expected to drive by highly unmet medical need owing lack of definitive treatment, advanced diagnostic process coupled rising awareness among healthcare professionals and patients alike across the globe. The Incidence and prevalence of primary biliary cholangitis vary geographically, ranging from 0.7 to 49 and 6.7 to 402 per million, respectively. The factors currently contributing to the revenue growth of the primary biliary cholangitis treatment market is increasing incidence and prevalence of the disease, increased exposure to environmental triggers to immune system such as pesticides. Furthermore, lifestyle changes like smoking, alcoholism, and obesity are expected to drive the market for primary biliary cholangitis treatment over the forecast period.

Request Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-3773

Global primary biliary cholangitis treatment market hindered by the lack of definitive treatment for the disease and late diagnosis of the disease led to treatment deprivation to the patient. The market restrained by dearth of epidemiology data which helps to assess the product access and availability in various geographies which are expected to hinder market revenue growth of primary biliary cholangitis treatment over the forecast period

Primary Biliary Cholangitis Treatment Market: Segmentation

Global primary biliary cholangitis treatment market has been segmented on the basis of treatment type, end user and Region.

Based on the treatmenttype, the global primary biliary cholangitis treatment market is segmented into the following:

For Treatment

Ursodeoxycholic acid

Obeticholic Acid

Methotrexate

Corticosteroids

Others

For Symptom Control

Antihistamines

Cholestyramine

Antibacterials

Opioid Antagonists

Colestipol

Others

Based on the end user, the global primary biliary cholangitis treatment market is segmented into the following:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Primary Biliary Cholangitis Treatment Market: Overview

Global primary biliary cholangitis treatment market is witnessing significant changes due to recent approval of UDCA by several regulatory authorities across the globe. In May 2016, the FDA approved obeticholic acid in combination with UDCA for primary biliary cholangitis (PBC) in adult patients with an inadequate response to UDCA. U.K’s NICE (National Institute for Health and Care Excellence) and European Commission granted the market authorization for Ocaliva (obeticholic acid) form Intercept Pharmaceuticals, Inc. in the year 2017 and 2016 respectively.

Primary Biliary Cholangitis Treatment Market: Region-wise Outlook

Geographically, Primary biliary cholangitis treatment market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America and Western Europe will remain key markets for primary biliary cholangitis treatment products due to increased regulatory approvals for treatment options, increasing awareness among patient advocacy groups regarding primary biliary cholangitis helps to maintain larger market share in the globalprimary biliary cholangitis treatment market by the regions. Asia Pacific is anticipated to present better growth opportunity owing to large untapped market, increasing out of pocket expenditure, and growing government’s interventions for improving healthcare infrastructure in the region.

Request to View TOC @ https://www.futuremarketinsights.com/toc/rep-gb-3773

Primary Biliary Cholangitis Treatment Market: Key Players

Some of the players in the global primary biliary cholangitis treatment market are Intercept Pharmaceuticals, Inc., Actavis, Inc., Teva Pharmaceuticals Inc., Epic Pharma, LLC, Mylan Pharmaceuticals Inc., and Axcan Scandipharm Inc.  to name a few.

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.
FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customised and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

U.S. Office, 616 Corporate Way, Suite 2-9018,, Valley Cottage, NY 10989,, United States, T: +1-347-9
616 Corporate Way, Suite 2-9018,

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Biliary Cholangitis (PBC) Treatment Market| 2017-2027 Key Players Intercept Pharmaceuticals, Inc., Actavis, Inc. here

News-ID: 1581731 • Views: 1146

More Releases from future market insights.

Facial Implants Market 2018 - 2028 | Key Players Include Implatech Associates In …
Facial implants are a type of medical device used to correct the facial structure or to provide more defined facial features including cheeks or chin & jawline. Facial Implants products are used for cosmetic reasons & are also used in medical crises such as accidents and injuries. Facial implants are also designed for augmentative or reconstructive surgeries. Facial implants give long lasting and permanent results that are a key factor
Pericarditis Treatment Market 2018 - 2028 | Pfizer Inc., Bayer AG, PerkinElmer I …
Global Pericarditis Treatment: Market Insights  Pericarditis is a cardiovascular disease which represents the swelling of the pericardium wall of the heart. The main cause of pericardium disease is the inflammation of pericardium wall which is generally caused by viral infection. Other causes of pericarditis disease are renal failure, bacterial infections and intake of some drugs such as procainamide. Some of the common symptoms of pericarditis disease are shortness of breath, fatigue, rapid
Aldosteronism Treatment Market Drivers and Restraints | 2018 - 2028 Key Players …
Aldosteronism is a type of hormonal disorder that occurs due to an imbalance in aldosterone and further leads to high blood pressure. In Aldosteronism, aldosterone is produced in excess by the adrenal gland that exceeds the normal body requirement. This causes the sodium levels to increase and lowers the potassium levels in the body. High levels of sodium in the blood lead to a high volume of blood and ultimately
Contouring Implants Market 2018 - 2028 | Key Players are ALPHA-HEALTH (ASIA) PTE …
Body Contouring refers to the medical-surgical procedure that alternates the shape of parts of the body via the removal of fat or skin. Body contouring implants procedures includes reshaping and resizing certain areas so the persons overall appearance is more balanced and in proportion. Body contouring implants are foreign materials that is made and molded prior to the person’s surgery and then inserted into the appropriate site. The body contouring

All 5 Releases


More Releases for Primary

Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include: 1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk
06-24-2020 | Health & Medicine
PENCIS
Global Conference on Primary Healthcare and Medicare
Healthcare conferences 2021 Paris, France organized by Pencis group. Pencis takes the privilege to invite speakers, participants, students, delegates, and exhibitors from across the globe to its Global Conference on Primary healthcare conferences 2021 and Medicare to be held in the beautiful city of Paris, France. Primary healthcare conferences 2021 is a discussion of common healthcare-related issues and additionally trade information, share proof, thoughts, and insight into advanced developments
RM Medical Search Places Primary Care Physician
RM Medical Search is pleased to announce the placement of a primary care physician with OnPoint Medical Group. OnPoint Medical Group is a Denver-based medical organization proudly led by physicians and supported by a team of proven business professionals. OnPoint Medical Group’s partnership with RM Medical Search, to find top quality physicians, furthers the organization's commitment “to make OnPoint Medical Group the preferred partner and advocate for providers and patients
Primary Hyperoxaluria - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Primary Hyperoxaluria - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Hyperoxaluria - Pipeline Review, H2 2017, provides an overview of the Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline landscape. Primary hyperoxaluria is a rare condition characterized by recurrent kidney and bladder stones. It
Primary Immunodeficiency Diseases Market: Key Insights
With only a handful of companies enjoying the major share of the revenue pie, the global primary immunodeficiency diseases (PIDD) market exhibits a consolidated vendor landscape. As per Transparency Market Research (TMR), CSL Behring LLC and Grifols S.A. emerged dominant in the market with a share of 60.5% in 2014. Baxter International, Inc. and Octapharma AG are other prominent enterprises operating in the global PIDD market. These companies have been
Primary Functions Marketing Resource Management Market Globally
MRM software is a software that helps in managing marketing operations effectively based on MRM processes. The primary functions of MRM are marketing planning and budgeting, asset management, project management, and content management. These systems also help connect an organization's marketing departments. Organizations use MRM systems to understand the buying criteria of consumers and to market accordingly. The benefits of MRM software are shown in the following exhibit. View Sample Copy